Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Viatris Inc.
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.
Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products.
Unilever, which has had three offers for GSK rebuffed, likely notes that the Federal Trade Commission and Department of Justice signal they will tighten scrutiny of deals that merge companies providing consumer-facing products and services.
Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.
- Generic Drugs
- Other Names / Subsidiaries
- Acton Pharmaceuticals, Inc.
- Agila, Bioniche Pharma Holdings Limited
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Dow B. Hickham
- Dow Hickam Pharmaceuticals, Inc.
- Generics (UK) Ltd.
- Jai Pharma
- Madaus Pharma
- Meda AB
- Meda Pharmaceuticals Inc.
- Mylan Inc.
- Mylan Laboratories Limited (formerly Matrix Laboratories Limited)
- Mylan Specialty (formerly Dey Pharma L.P.)
- Rottapharm Madaus
- Mylan Technologies, Inc.
- UDL Laboratories
- Viatris Inc.